FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Virus genes2010; 41(1); 86-98; doi: 10.1007/s11262-010-0491-6

Genomic analysis of an effective lentiviral vaccine-attenuated equine infectious anemia virus vaccine EIAV FDDV13.

Abstract: Chinese equine infectious anemia virus (EIAV) attenuated vaccine is the first lentiviral vaccine with a successful application. In order to understand the correlation of viral genomic mutations with viral attenuation and with induced immunoprotective properties, we analyzed the proviral genome sequences of the EIAV-attenuated vaccine strain EIAV(FDDV13) (EIAV fetal donkey dermal cell-adapted vaccine) and its highly virulent parental strain EIAV(LN40). The sequences of these strains were compared with those of the major foreign EIAV strains. The results indicated a large genetic distance between the Chinese EIAV strain and the major EIAV strains in America and Japan. The Chinese strains belong to an independent phylogenetic branch. The divergence between the entire genome of the Chinese strains and that of other major EIAV strains is approximately 23%. The divergence rate in LTR is over 14%, whereas that in each open reading frame is over 20%. The gp90 exhibited a divergence of 35% in its nucleotide sequence and 40% in its amino acid sequence. The present study found that after long-term passage in vitro, EIAV(FDDV13) has accumulated many stable substitution mutations in each gene. These mutations at multiple sites in multiple genes of the vaccine strain, especially the conserved mutations, provide important references for further understanding the attenuation mechanism of Chinese EIAV-attenuated vaccine and the immunoprotection mechanism of lentiviral vaccines.
Get Full Text
Publication Date: 2010-06-05 PubMed ID: 20526660DOI: 10.1007/s11262-010-0491-6Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The abstract describes the genomic analysis of a successful Chinese lentiviral vaccine strain, EIAV FDDV13, against the equine infectious anemia virus (EIAV). The study compares this attenuated vaccine strain with its virulent parent strain and other major EIAV strains from America and Japan, highlighting substantial genetic difference, and mutations that may contribute to the vaccine’s effectiveness.

Genome Analysis of the Chinese Lentiviral Vaccine EIAV FDDV13

  • The study conducts a genomic analysis of a Chinese EIAV vaccine, EIAV FDDV13, and its highly virulent parental strain, EIAV(LN40). This analysis focuses on understanding the correlation between genomic mutations in the virus and its attenuation and immunoprotective properties.
  • The sequences of these strains were compared with that of major EIAV strains in the US and Japan.
  • Researchers found significant genetic variance between the Chinese EIAV strain and the major EIAV strains in other countries, with the Chinese strains forming an independent phylogenetic branch.

Genetic Divergence

  • The divergence between the genome of the Chinese strains and that of the other major EIAV strains is placed at approximately 23%.
  • The study also found that the divergence rate in the Long terminal Repeat (LTR) is over 14%, while each open reading frame has a divergence rate of over 20%.
  • The gp90 showed substantial change, displaying a divergence of 35% in nucleotide sequence and 40% in its amino acid sequence.

Mutations and their Effects

  • The research identified that after long-term passage in vitro, EIAV(FDDV13) accumulated many stable substitution mutations in each gene.
  • The multiple mutations at different sites are thought to contribute to the successful attenuation of the vaccine strain, especially the conserved mutations.
  • The findings from this research provide important reference points for understanding the attenuation of Chinese EIAV vaccine and the immune protection mechanism of lentiviral vaccines in general.

Cite This Article

APA
Qi X, Wang X, Wang S, Lin Y, Jiang C, Ma J, Zhao L, Lv X, Shen R, Wang F, Kong X, Su Z, Zhou J. (2010). Genomic analysis of an effective lentiviral vaccine-attenuated equine infectious anemia virus vaccine EIAV FDDV13. Virus Genes, 41(1), 86-98. https://doi.org/10.1007/s11262-010-0491-6

Publication

Virus genes
ISSN: 1572-994X
NlmUniqueID: 8803967
Country: United States
Language: English
Volume: 41
Issue: 1
Pages: 86-98

Researcher Affiliations

Qi, Xu
  • Department of Neurology, First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
Wang, Xuefeng
    Wang, Shuai
      Lin, Yuezhi
        Jiang, Chenggang
          Ma, Jian
            Zhao, Liping
              Lv, Xiaoling
                Shen, Rongxian
                  Wang, Fenglong
                    Kong, Xiangang
                      Su, Zhiqiang
                        Zhou, Jianhua

                          MeSH Terms

                          • Base Sequence
                          • Genome, Viral
                          • Infectious Anemia Virus, Equine / genetics
                          • Infectious Anemia Virus, Equine / immunology
                          • Molecular Sequence Data
                          • Mutation
                          • Phylogeny
                          • Sequence Alignment
                          • Vaccines, Attenuated / immunology
                          • Viral Vaccines / immunology

                          References

                          This article includes 45 references
                          1. Leroux C, Cadoré JL, Montelaro RC. Equine Infectious Anemia Virus (EIAV): what has HIV's country cousin got to tell us?. Vet Res 2004 Jul-Aug;35(4):485-512.
                            pubmed: 15236678doi: 10.1051/vetres:2004020google scholar: lookup
                          2. Si Z, Cayabyab M, Sodroski J. Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys.. J Virol 2001 May;75(9):4208-18.
                            pubmed: 11287570doi: 10.1128/JVI.75.9.4208-4218.2001google scholar: lookup
                          3. Li F, Leroux C, Craigo JK, Cook SJ, Issel CJ, Montelaro RC. The S2 gene of equine infectious anemia virus is a highly conserved determinant of viral replication and virulence properties in experimentally infected ponies.. J Virol 2000 Jan;74(1):573-9.
                            pubmed: 10590152doi: 10.1128/jvi.74.1.573-579.2000google scholar: lookup
                          4. Cheng-Mayer C, Brown A, Harouse J, Luciw PA, Mayer AJ. Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.. J Virol 1999 Jul;73(7):5294-300.
                            pubmed: 10364275doi: 10.1128/JVI.73.7.5294-5300.1999google scholar: lookup
                          5. Issel CJ, Coggins L. Equine infectious anemia: current knowledge.. J Am Vet Med Assoc 1979 Apr 1;174(7):727-33.
                            pubmed: 218920
                          6. Chen SS, Lee SF, Wang CT. Cellular membrane-binding ability of the C-terminal cytoplasmic domain of human immunodeficiency virus type 1 envelope transmembrane protein gp41.. J Virol 2001 Oct;75(20):9925-38.
                            pubmed: 11559825doi: 10.1128/JVI.75.20.9925-9938.2001google scholar: lookup
                          7. Tagmyer TL, Craigo JK, Cook SJ, Even DL, Issel CJ, Montelaro RC. Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition.. J Virol 2008 Apr;82(8):4052-63.
                            pubmed: 18234792doi: 10.1128/JVI.02028-07google scholar: lookup
                          8. Rice NR, Lequarre AS, Casey JW, Lahn S, Stephens RM, Edwards J. Viral DNA in horses infected with equine infectious anemia virus.. J Virol 1989 Dec;63(12):5194-200.
                            pubmed: 2555550doi: 10.1128/JVI.63.12.5194-5200.1989google scholar: lookup
                          9. Stevenson M. Portals of entry: uncovering HIV nuclear transport pathways.. Trends Cell Biol 1996 Jan;6(1):9-15.
                            pubmed: 15157526doi: 10.1016/0962-8924(96)81032-4google scholar: lookup
                          10. Howe L, Leroux C, Issel CJ, Montelaro RC. Equine infectious anemia virus envelope evolution in vivo during persistent infection progressively increases resistance to in vitro serum antibody neutralization as a dominant phenotype.. J Virol 2002 Nov;76(21):10588-97.
                            pubmed: 12368301doi: 10.1128/jvi.76.21.10588-10597.2002google scholar: lookup
                          11. Zielonka J, Bravo IG, Marino D, Conrad E, Perković M, Battenberg M, Cichutek K, Münk C. Restriction of equine infectious anemia virus by equine APOBEC3 cytidine deaminases.. J Virol 2009 Aug;83(15):7547-59.
                            pubmed: 19458006doi: 10.1128/JVI.00015-09google scholar: lookup
                          12. Li F, Craigo JK, Howe L, Steckbeck JD, Cook S, Issel C, Montelaro RC. A live attenuated equine infectious anemia virus proviral vaccine with a modified S2 gene provides protection from detectable infection by intravenous virulent virus challenge of experimentally inoculated horses.. J Virol 2003 Jul;77(13):7244-53.
                            pubmed: 12805423doi: 10.1128/jvi.77.13.7244-7253.2003google scholar: lookup
                          13. Bukrinsky MI, Haggerty S, Dempsey MP, Sharova N, Adzhubel A, Spitz L, Lewis P, Goldfarb D, Emerman M, Stevenson M. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells.. Nature 1993 Oct 14;365(6447):666-9.
                            pubmed: 8105392doi: 10.1038/365666a0google scholar: lookup
                          14. Leroux C, Issel CJ, Montelaro RC. Novel and dynamic evolution of equine infectious anemia virus genomic quasispecies associated with sequential disease cycles in an experimentally infected pony.. J Virol 1997 Dec;71(12):9627-39.
                            pubmed: 9371627doi: 10.1128/JVI.71.12.9627-9639.1997google scholar: lookup
                          15. Schiltz RL, Shih DS, Rasty S, Montelaro RC, Rushlow KE. Equine infectious anemia virus gene expression: characterization of the RNA splicing pattern and the protein products encoded by open reading frames S1 and S2.. J Virol 1992 Jun;66(6):3455-65.
                            pubmed: 1316461doi: 10.1128/JVI.66.6.3455-3465.1992google scholar: lookup
                          16. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V, Haynes B, Hahn BH, Bhattacharya T, Korber B. Diversity considerations in HIV-1 vaccine selection.. Science 2002 Jun 28;296(5577):2354-60.
                            pubmed: 12089434doi: 10.1126/science.1070441google scholar: lookup
                          17. Koff WC, Johnson PR, Watkins DI, Burton DR, Lifson JD, Hasenkrug KJ, McDermott AB, Schultz A, Zamb TJ, Boyle R, Desrosiers RC. HIV vaccine design: insights from live attenuated SIV vaccines.. Nat Immunol 2006 Jan;7(1):19-23.
                            pubmed: 16357854doi: 10.1038/ni1296google scholar: lookup
                          18. Rudensey LM, Kimata JT, Long EM, Chackerian B, Overbaugh J. Changes in the extracellular envelope glycoprotein of variants that evolve during the course of simian immunodeficiency virus SIVMne infection affect neutralizing antibody recognition, syncytium formation, and macrophage tropism but not replication, cytopathicity, or CCR-5 coreceptor recognition.. J Virol 1998 Jan;72(1):209-17.
                            pubmed: 9420217doi: 10.1128/JVI.72.1.209-217.1998google scholar: lookup
                          19. Zhou T, Yuan XF, Hou SH, Tu YB, Peng JM, Wen JX, Qiu HJ, Wu DL, Chen HC, Wang XJ, Tong GZ. Long terminal repeat sequences from virulent and attenuated equine infectious anemia virus demonstrate distinct promoter activities.. Virus Res 2007 Sep;128(1-2):58-64.
                            pubmed: 17499380doi: 10.1016/j.virusres.2007.04.005google scholar: lookup
                          20. Lichtenstein DL, Craigo JK, Leroux C, Rushlow KE, Cook RF, Cook SJ, Issel CJ, Montelaro RC. Effects of long terminal repeat sequence variation on equine infectious anemia virus replication in vitro and in vivo.. Virology 1999 Oct 25;263(2):408-17.
                            pubmed: 10544113doi: 10.1006/viro.1999.9921google scholar: lookup
                          21. Belshan M, Harris ME, Shoemaker AE, Hope TJ, Carpenter S. Biological characterization of Rev variation in equine infectious anemia virus.. J Virol 1998 May;72(5):4421-6.
                            pubmed: 9557734doi: 10.1128/JVI.72.5.4421-4426.1998google scholar: lookup
                          22. Maury W, Perryman S, Oaks JL, Seid BK, Crawford T, McGuire T, Carpenter S. Localized sequence heterogeneity in the long terminal repeats of in vivo isolates of equine infectious anemia virus.. J Virol 1997 Jul;71(7):4929-37.
                            pubmed: 9188555doi: 10.1128/JVI.71.7.4929-4937.1997google scholar: lookup
                          23. Payne SL, Fuller FJ. Virulence determinants of equine infectious anemia virus.. Curr HIV Res 2010 Jan;8(1):66-72.
                            pubmed: 20210781doi: 10.2174/157016210790416352google scholar: lookup
                          24. Jiang S, Song R, Popov S, Mirshahidi S, Ruprecht RM. Overlapping synthetic peptides as vaccines.. Vaccine 2006 Sep 11;24(37-39):6356-65.
                            pubmed: 16793181doi: 10.1016/j.vaccine.2006.04.070google scholar: lookup
                          25. Craigo JK, Zhang B, Barnes S, Tagmyer TL, Cook SJ, Issel CJ, Montelaro RC. Envelope variation as a primary determinant of lentiviral vaccine efficacy.. Proc Natl Acad Sci U S A 2007 Sep 18;104(38):15105-10.
                            pubmed: 17846425doi: 10.1073/pnas.0706449104google scholar: lookup
                          26. Carvalho M, Derse D. Mutational analysis of the equine infectious anemia virus Tat-responsive element.. J Virol 1991 Jul;65(7):3468-74.
                            pubmed: 1645778doi: 10.1128/JVI.65.7.3468-3474.1991google scholar: lookup
                          27. Threadgill DS, Steagall WK, Flaherty MT, Fuller FJ, Perry ST, Rushlow KE, Le Grice SF, Payne SL. Characterization of equine infectious anemia virus dUTPase: growth properties of a dUTPase-deficient mutant.. J Virol 1993 May;67(5):2592-600.
                            pubmed: 8386267doi: 10.1128/JVI.67.5.2592-2600.1993google scholar: lookup
                          28. Henson JB, McGuire TC. Immunopathology of equine infectious anemia.. Am J Clin Pathol 1971 Sep;56(3):306-13.
                            pubmed: 4328671doi: 10.1093/ajcp/56.3.306google scholar: lookup
                          29. Payne SL, Elder JH. The role of retroviral dUTPases in replication and virulence.. Curr Protein Pept Sci 2001 Dec;2(4):381-8.
                            pubmed: 12374097doi: 10.2174/1389203013381008google scholar: lookup
                          30. Payne SL, La Celle K, Pei XF, Qi XM, Shao H, Steagall WK, Perry S, Fuller F. Long terminal repeat sequences of equine infectious anaemia virus are a major determinant of cell tropism.. J Gen Virol 1999 Mar;80 ( Pt 3):755-759.
                            pubmed: 10092016doi: 10.1099/0022-1317-80-3-755google scholar: lookup
                          31. Li F, Puffer BA, Montelaro RC. The S2 gene of equine infectious anemia virus is dispensable for viral replication in vitro.. J Virol 1998 Oct;72(10):8344-8.
                            pubmed: 9733881doi: 10.1128/JVI.72.10.8344-8348.1998google scholar: lookup
                          32. Luciw PA, Mandell CP, Himathongkham S, Li J, Low TA, Schmidt KA, Shaw KE, Cheng-Mayer C. Fatal immunopathogenesis by SIV/HIV-1 (SHIV) containing a variant form of the HIV-1SF33 env gene in juvenile and newborn rhesus macaques.. Virology 1999 Oct 10;263(1):112-27.
                            pubmed: 10544087doi: 10.1006/viro.1999.9908google scholar: lookup
                          33. Malmquist WA, Barnett D, Becvar CS. Production of equine infectious anemia antigen in a persistently infected cell line.. Arch Gesamte Virusforsch 1973;42(4):361-70.
                            pubmed: 4358259doi: 10.1007/BF01250717google scholar: lookup
                          34. Wei L, Fan X, Lu X, Zhao L, Xiang W, Zhang X, Xue F, Shao Y, Shen R, Wang X. Genetic variation in the long terminal repeat associated with the transition of Chinese equine infectious anemia virus from virulence to avirulence.. Virus Genes 2009 Apr;38(2):285-8.
                            pubmed: 19130201doi: 10.1007/s11262-008-0317-ygoogle scholar: lookup
                          35. Lichtenstein DL, Rushlow KE, Cook RF, Raabe ML, Swardson CJ, Kociba GJ, Issel CJ, Montelaro RC. Replication in vitro and in vivo of an equine infectious anemia virus mutant deficient in dUTPase activity.. J Virol 1995 May;69(5):2881-8.
                            pubmed: 7707512doi: 10.1128/JVI.69.5.2881-2888.1995google scholar: lookup
                          36. Liang H, He X, Shen RX, Shen T, Tong X, Ma Y, Xiang WH, Zhang XY, Shao YM. Combined amino acid mutations occurring in the envelope closely correlate with pathogenicity of EIAV.. Arch Virol 2006 Jul;151(7):1387-403.
                            pubmed: 16502285doi: 10.1007/s00705-005-0718-3google scholar: lookup
                          37. Hoffman DW, White SW. NMR analysis of the trans-activation response (TAR) RNA element of equine infectious anemia virus.. Nucleic Acids Res 1995 Oct 25;23(20):4058-65.
                            pubmed: 7479065doi: 10.1093/nar/23.20.4058google scholar: lookup
                          38. Hoffman DW, Colvin RA, Garcia-Blanco MA, White SW. Structural features of the trans-activation response RNA element of equine infectious anemia virus.. Biochemistry 1993 Feb 2;32(4):1096-104.
                            pubmed: 8381023doi: 10.1021/bi00055a015google scholar: lookup
                          39. Chackerian B, Rudensey LM, Overbaugh J. Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies.. J Virol 1997 Oct;71(10):7719-27.
                            pubmed: 9311856doi: 10.1128/JVI.71.10.7719-7727.1997google scholar: lookup
                          40. Steagall WK, Robek MD, Perry ST, Fuller FJ, Payne SL. Incorporation of uracil into viral DNA correlates with reduced replication of EIAV in macrophages.. Virology 1995 Jul 10;210(2):302-13.
                            pubmed: 7542416doi: 10.1006/viro.1995.1347google scholar: lookup
                          41. Rice NR, Henderson LE, Sowder RC, Copeland TD, Oroszlan S, Edwards JF. Synthesis and processing of the transmembrane envelope protein of equine infectious anemia virus.. J Virol 1990 Aug;64(8):3770-8.
                            pubmed: 2164597doi: 10.1128/JVI.64.8.3770-3778.1990google scholar: lookup
                          42. Zheng YH, Sentsui H, Sugita M, Nakaya T, Kishi M, Hagiwara K, Inoshima Y, Ishihara C, Kono Y, Lu JL, Ikuta K. Replication ability in vitro and in vivo of equine infectious anemia virus avirulent Japanese strain.. Virology 2000 Jan 5;266(1):129-39.
                            pubmed: 10612667doi: 10.1006/viro.1999.0076google scholar: lookup
                          43. Oldstone MB. Viral persistence.. Cell 1989 Feb 24;56(4):517-20.
                            pubmed: 2645053doi: 10.1016/0092-8674(89)90573-4google scholar: lookup
                          44. Shen T, Liang H, Tong X, Fan X, He X, Ma Y, Xiang W, Shen R, Zhang X, Shao Y. Amino acid mutations of the infectious clone from Chinese EIAV attenuated vaccine resulted in reversion of virulence.. Vaccine 2006 Feb 6;24(6):738-49.
                            pubmed: 16202485doi: 10.1016/j.vaccine.2005.08.084google scholar: lookup
                          45. Ma J, Jiang C, Lin Y, Wang X, Zhao L, Xiang W, Shao Y, Shen R, Kong X, Zhou J. In vivo evolution of the gp90 gene and consistently low plasma viral load during transient immune suppression demonstrate the safety of an attenuated equine infectious anemia virus (EIAV) vaccine.. Arch Virol 2009;154(5):867-73.
                            pubmed: 19363668doi: 10.1007/s00705-009-0378-9google scholar: lookup

                          Citations

                          This article has been cited 9 times.
                          1. Wang XF, Wang YH, Bai B, Zhang M, Chen J, Zhang X, Gao M, Wang X. Truncation of the Cytoplasmic Tail of Equine Infectious Anemia Virus Increases Virion Production by Improving Env Cleavage and Plasma Membrane Localization. J Virol 2021 Nov 9;95(23):e0108721.
                            doi: 10.1128/JVI.01087-21pubmed: 34495693google scholar: lookup
                          2. Wang XF, Liu Q, Wang YH, Wang S, Chen J, Lin YZ, Ma J, Zhou JH, Wang X. Characterization of Equine Infectious Anemia Virus Long Terminal Repeat Quasispecies In Vitro and In Vivo. J Virol 2018 Apr 15;92(8).
                            doi: 10.1128/JVI.02150-17pubmed: 29386282google scholar: lookup
                          3. Han X, Zhang P, Yu W, Xiang W, Li X. Amino acid mutations in the env gp90 protein that modify N-linked glycosylation of the Chinese EIAV vaccine strain enhance resistance to neutralizing antibodies. Virus Genes 2016 Dec;52(6):814-822.
                            doi: 10.1007/s11262-016-1382-2pubmed: 27572122google scholar: lookup
                          4. Wang XF, Lin YZ, Li Q, Liu Q, Zhao WW, Du C, Chen J, Wang X, Zhou JH. Genetic Evolution during the development of an attenuated EIAV vaccine. Retrovirology 2016 Feb 3;13:9.
                            doi: 10.1186/s12977-016-0240-6pubmed: 26842878google scholar: lookup
                          5. Liu Q, Wang XF, Ma J, He XJ, Wang XJ, Zhou JH. Characterization of Equine Infectious Anemia Virus Integration in the Horse Genome. Viruses 2015 Jun 19;7(6):3241-60.
                            doi: 10.3390/v7062769pubmed: 26102582google scholar: lookup
                          6. Qian L, Han X, Liu X. Structural insight into equine lentivirus receptor 1. Protein Sci 2015 May;24(5):633-42.
                            doi: 10.1002/pro.2634pubmed: 25559821google scholar: lookup
                          7. Ma J, Wang SS, Lin YZ, Liu HF, Liu Q, Wei HM, Wang XF, Wang YH, Du C, Kong XG, Zhou JH, Wang X. Infection of equine monocyte-derived macrophages with an attenuated equine infectious anemia virus (EIAV) strain induces a strong resistance to the infection by a virulent EIAV strain. Vet Res 2014 Aug 9;45(1):82.
                            doi: 10.1186/s13567-014-0082-ypubmed: 25106750google scholar: lookup
                          8. Sun PL, Lv SX, Zhou JH, Liu XQ. Cloning, expression and preliminary crystallographic analysis of the equine infectious anaemia virus (EIAV) gp45 ectodomain. Acta Crystallogr Sect F Struct Biol Cryst Commun 2011 Apr 1;67(Pt 4):482-5.
                            doi: 10.1107/S174430911100460Xpubmed: 21505247google scholar: lookup
                          9. Wang X, Wang S, Lin Y, Jiang C, Ma J, Zhao L, Lv X, Wang F, Shen R, Zhou J. Unique evolution characteristics of the envelope protein of EIAV(LN₄₀), a virulent strain of equine infectious anemia virus. Virus Genes 2011 Apr;42(2):220-8.
                            doi: 10.1007/s11262-010-0563-7pubmed: 21369830google scholar: lookup
                          Subscribe to our newsletter
                          Join 99,911 horse owners like you who receive our email updates on horse health and nutrition.